Old Web
English
Sign In
Acemap
>
authorDetail
>
Michael Toole
Michael Toole
University of Michigan
Medicine
Stable Disease
Immunotherapy
Renal cell carcinoma
Interleukin 2
3
Papers
25
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2
2016
Cancer Immunology, Immunotherapy
David D. Stenehjem
Michael Toole
Joseph Merriman
Kinjal Parikh
Stephanie Daignault
Sarah Scarlett
Peg Esper
Katherine A. Skinner
Aaron M. Udager
Srinivas K. Tantravahi
David Gill
Alli M. Straubhar
Archana M. Agarwal
Kenneth F. Grossmann
Wolfram E. Samlowski
Bruce G. Redman
Neeraj Agarwal
Ajjai Alva
Show All
Source
Cite
Save
Citations (10)
Extension of overall survival (OS) beyond objective responses (OR) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2).
2015
Journal of Clinical Oncology
David D. Stenehjem
Michael Toole
Joseph Merriman
Kinjal Parikh
Stephanie Daignault
Sarah Scarlett
Peg Esper
Katherine Skinner
Aaron M. Udager
Srinivas K. Tantravahi
Alli M. Straubhar
Archana M. Agarwal
Joan Van Atta
Kenneth F. Grossmann
Wolfram E. Samlowski
Bruce G. Redman
Neeraj Agarwal
Ajjai Alva
Show All
Source
Cite
Save
Citations (0)
Oncotype Dx Results in Multiple Primary Breast Cancers
2014
Michael Toole
Kelley M. Kidwell
Catherine Van Poznak
Show All
Source
Cite
Save
Citations (15)
1